Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024. 

"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."

Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month. 

The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses. 

Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent. 

Share:
More In Business
Earnings Breakdown for Options Traders
Cheddar News' reporter Angela Miles reports from the Cboe floor with Scott Bauer, CEO of the Prosper Trading Academy, to break down Apple, Moderna, and Datadog earnings for options traders.
Stretching Your Dollar: Understanding Life Insurance Loans
Tom McNeela, chief RIA solutions officer with RetireOne, joined Cheddar News to explain how people can use their life insurance policies for an emergency loan. "There's a lot of advantages and opportunities with permanent life insurance policy," he said, "if you have one, and there's cash value in there, you can take a loan out, and most of the time, it's a better rate than what you can get at your bank."
Load More